Webcasts Main Sessions and Satellites ISAL XVII
Program Acute Leukemias XVII
Main Session I: Epigenetic Changes in Acute Leukemias
Sunday, February 24, 2019
Main Session II: Clonal Evolution of Acute Leukemias and Leukemic Stem Cells
Sunday, February 24, 2019
- S. Jaiswal, Stanford, CA, USA: Clonal Hematopoiesis of Indeterminate Potential
- L. Shlush, Rehovot, ISL: Predicting Leukemia Development from Preleukemic Clonal
- A. Trumpp, Heidelberg, DE: Linking Metabolic Clues to Epigenomics in AML Stem Cells
- P. Vyas, Oxford, UK: Clonal Evolution under IDH Inhibitor Therapy
Opening Session
Monday, February 25, 2019
- W. Hiddemann, Munich, DE: Welcome Address / Thomas-Büchner Lecture
- J. DiPersio, St. Louis, MO, USA: From Cell Kinetics to Targeted Therapy
Main Session III: Genetic and Molecular Characterization of AML: Novel Markers for Diagnosis and Prognosis
Monday, February 25, 2019
- M. Gerstung, Hinxton, UK: Genetic Landscape of AML and its Relevance for Treatment
- R. Itzykson, Paris, F: Clonal Interference of Signaling Mutations in AML
- K. Metzeler, Munich, DE: Persistence of Preleukemic Clones in AML
- M. Konopleva, Houston, TX, USA: Targeting BCL2
Main Session IV: Novel Approaches and Targeted Therapies in AML
Monday, February 25, 2019
- M.J. Levis, Baltimore, MD, USA: New FLT3 Inhibitors
- Th. Oellerich, Frankfurt, DE: SYK Inhibitors in AML
- C. DiNardo, Houston, TX, USA: IDH1 and IDH2 Inhibitors
Main Session VI: Risk Adapted Therapy of AML
Tuesday, February 26, 2019
- J.E. Lancet, Rochester, NY, USA: Innovations in Conventional Chemotherapy (CPX 351)
- D. Reinhardt, Essen, DE: Risk Adapted Therapy of Childhood AML
Main Session VII: Biology and Treatment of APL
Tuesday, February 26, 2019
- F. Lo Coco, Rome, I: APL – Biology and Treatment
- U. Platzbecker, Leipzig, DE: Current Studies in APL
- H.-H. Zhu, Bejing, CHN: Oral Arsenic for the Treatment of APL
Main Session VIII: Relevance of MRD in Acute Leukemias
Tuesday, February 26, 2019
Main Session X: Immunotherapy for Acute Leukemias
Wednesday, February 27, 2019
- N.G. Daver, Houston, TX, USA: Checkpoint Inhibitor based Combination Approaches in AML/MDS
- Z. Berneman, Antwerpen, NL: DC Vaccination in AML
- M. Subklewe, Munich, DE: Harnessing the T-Cell Response in AML
Main Session XI: ALL: Biology and Treatment Strategies of ALL
Wednesday, February 27, 2019
- E.J. Jabbour, Houston, TX, USA: Treatment Strategies in ALL
- N. Gökbuget, Frankfurt, DE: Blina in MRD + ALL
Webcasts Satellite Symposia ISAL XVII
Satellite Symposium AMGEN
Sunday, February 24, 2019
- Prof Max Topp, University of Würzburg, Germany: Targeted therapy of acute leukaemia: present achievements and future potential
- Prof Marion Subklewe, University Hospital of Munich, Germany: Bispecific antibody constructs for the treatment of AML
Satellite Symposium JAZZ Pharmaceuticals
Monday, February 25, 2019
- L. Bullinger, Berlin, DE: Diagnosing high-risk AML: WHO and what?
- M.S.Tallman, New York, NY, USA: Practice Changing Treatments in AML - Established Standard of Care
Satellite Symposium Pfizer
Tuesday, February 26, 2019